A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation

• Hauptverfasser: Nan Zhao (Verfasst von), Zhiyan Liu (Verfasst von), Qiufen Xie (Verfasst von), Zhe Wang (Verfasst von), Zhongyi Sun (Verfasst von), Qian Xiang (Verfasst von), Yimin Cui (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: The rivaroxaban dose regimen for patients with nonvalvular atrial fibrillation (NVAF) is complex in Asia. Given the high interindividual variability and the risk of bleeding caused by rivaroxaban in Asians, the influencing factors and the relationship between outlier biomarkers and bleed...